Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

Rosiglitazone vs. Pioglitazone: A Comparison of Cardiovascular Outcomes

Results of a large observational study provide more evidence that rosiglitazone increases cardiovascular risk.

Sign In

Don't yet have a username or password?

Journal Watch e-mail alerts and unlimited online access to articles 6 months after publication.

Full, immediate online access to all Journal Watch content and services.

Already a subscriber? Activate your subscription to receive full online access.

Get full site access with a 7-day site pass for $19